← Browse by Condition
Medical Condition
aml with gene mutations
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1
ClinicalMetric tracks all active clinical trials for aml with gene mutations sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 2
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT06366789 Phase 1
Recruiting
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
Enrollment
150 pts
Location
United States, Austr...
Sponsor
Lomond Therapeutics Holdings, ...
NCT06313437 Phase 1
Recruiting
Revumenib in Combination With 7+3 + Midostaurin in AML
Enrollment
22 pts
Location
United States
Sponsor
Richard Stone, MD
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology